Skip to main content

3 Result(s)

within E. Mascia Remove this filter

and

  1. No Access

    Article

    Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients

    Fingolimod (FTY), a second-line oral drug approved for relapsing remitting Multiple Sclerosis (RRMS) acts in preventing lymphocyte migration outside lymph nodes; moreover, several lines of evidence suggest tha...

    G. Sferruzza, F. Clarelli, E. Mascia, L. Ferrè, L. Ottoboni… in Molecular Neurobiology (2021)

  2. No Access

    Article

    Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod

    Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs.

    L. Ferre’, F. Clarelli, G. Sferruzza, M. A. Rocca, E. Mascia… in Neurological Sciences (2018)

  3. No Access

    Article

    Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis

    The aim of the study is the identification of genetic factors that influence the long-term response to interferon-β (IFNβ) (4-year follow-up). We performed a genome-wide association study in 337 IFNβ-treated I...

    F Clarelli, G Liberatore, M Sorosina, A M Osiceanu… in The Pharmacogenomics Journal (2017)